Form 4: Galectin Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc, sold 16,250 shares of common stock on July 14, 2026 for $5.13 per share.
Summary
- Option exercise/conversion: acquired 16,250 Common Stock at $3.04 ($49,400) on July 14, 2026; holds 16,250 after (Direct).
- Open-market sale: disposed of 16,250 Common Stock at $5.13 ($83,284) on July 14, 2026 (Direct).
- Option exercise/conversion: disposed of 16,250 Stock option (right to buy) on July 14, 2026; holds 48,750 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $83,284 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Khurram Jamil — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-14 | Option exercise/conversion | Common Stock | 16,250 | $3 | $49.4K | 16,250 |
| 2026-07-14 | Open-market sale | Common Stock | 16,250 | $5 | $83.3K | 0 |
| 2026-07-14 | Option exercise/conversion | Stock option (right to buy) | 16,250 | — | — | 48,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-14 | Option exercise/conversion (16,250 shares) |
| 2026-07-14 | Open-market sale (16,250 shares) |
| 2026-07-14 | Option exercise/conversion (16,250 shares) |
Keywords
insider transaction, Form 4, GALT, GALECTIN THERAPEUTICS INC, bearish, Khurram Jamil
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.